Prijavite neželjenu reakciju
Serbia
Bulgaria
CZECH REPUBLIC
Denmark
Finland
International
Latvia
Netherlands
Norway
Poland
Romania
Russia
Slovakia
Slovenia
Spain
Sweden
Ukraine
Austria
Asean
Schizophrenia
Log in required
Local regulations restrict this content to healthcare professionals
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/"target="_blank">Login</a>
What is Schizophrenia?
Neurochemical basis of schizophrenia
Negative Symptoms
The Challenge of Negative Symptoms in Schizophrenia
Diagnosis
The Challenge of Diagnosing Negative Symptoms
Treatment
Burden
Log in required
Local regulations restrict this content to healthcare professionals
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/" target="_blank">Login</a>
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/" target="_blank">Login</a>
Treating Negative Symptoms of Schizophrenia
Lifestyle
How physical exercise helps individuals with schizophrenia
Our Product
Log in required
Local regulations restrict this content to healthcare professionals
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/"target="_blank">Login</a>
Log in required
Local regulations restrict this content to healthcare professionals
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/" target="_blank">Login</a>
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/" target="_blank">Login</a>
Mode of Action
The Mechanism of Action of Our Product
Log in required
Local regulations restrict this content to healthcare professionals
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/" target="_blank">Login</a>
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/" target="_blank">Login</a>
Clinical Data
Efficacy
Our Product in patients with acute exacerbation of schizophrenia
Cariprazine in the Long-Term Treatment of Schizophrenia
Cariprazine Controls Negative Symptoms in Schizophrenia
Controlling Everyday Functioning with Cariprazine
Cariprazine's Effects on Primary and Secondary Negative Symptoms: The Pseudospecificity Problem
Safety
The Safety and Tolerability Profile of Our Product
The Management of Akathisia
Our product and Weight Gain
Log in required
Local regulations restrict this content to healthcare professionals
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/" target="_blank">Login</a>
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/" target="_blank">Login</a>
Prescribing Our Product
Initiating
Switching
Dosing
Drug-drug Interactions
Experience our product
Log in required
Local regulations restrict this content to healthcare professionals
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/"target="_blank">Login</a>
Patients suitable for our product
PATIENT SERIES: ACUTE PATIENTS
PATIENT SERIES: PATIENTS WITH NEGATIVE SYMPTOMS
PATIENT SERIES: THE SUBACUTE PATIENT
PATIENT SERIES: PATIENTS WITH THERAPEUTIC COMPROMISE – LACK OF EFFICACY
PATIENT SERIES: PATIENTS WITH THERAPEUTIC COMPROMISE – SAFETY ISSUES
Log in required
Local regulations restrict this content to healthcare professionals
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/" target="_blank">Login</a>
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/" target="_blank">Login</a>
Patient cases
A clinical case of patient with early psychosis treated with cariprazine
Our product add-on in inadequate clozapine response: a case study
Case Study of a Drug-Naïve Female Patient Treated With Cariprazine
Our product add-on in inadequate clozapine response: another case study
Early psychosis treated with cariprazine: a case study
Education & Resources
Log in required
Local regulations restrict this content to healthcare professionals
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/"target="_blank">Login</a>
Log in required
Local regulations restrict this content to healthcare professionals
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/" target="_blank">Login</a>
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/" target="_blank">Login</a>
Diagnostic Tools
Diagnostic Tools
Interviews
Antagonist or partial agonist – which one is the best drug?
The role of partial agonists in schizophrenia treatment: managing the clinical aspects - ECNP 2020
Treatment with our product to address schizophrenia needs - ECNP 2020
Literature Review
Schizophrenia: negative symptoms
Cariprazine in the treatment of schizophrenia in clinical research and the real-world
The safety of recently developed antipsychotics
Dose-response in antipsychotics
Dosing antipsychotics in acute schizophrenia
Clinical guide for treating negative symptoms in schizophrenia
Understanding the pathophysiology of the negative symptom dimensions of schizophrenia
Validation of the PANSS in two-factor negative symptom distinction
Benefits of Antipsychotic Polypharmacy in Schizophrenia Maintenance Therapy
Schizophrenia: Is It All Down To Your Genes?
Causal Relationship Between Cognitive Deficit and Risk of Schizophrenia
Connection Between Inflammation and Schizophrenia?
Potential benefits of using eHealth in the management of schizophrenia
Markers of Inflammation and Infection in Schizophrenia
The Role of Cannabis in Treatment-Resistant Schizophrenia
Childhood Behaviour to Predict Psychosis-Spectrum Diagnoses in Adulthood
Suicide Prevention
Investigating the Stigma Around Mental Health and When People Seek Professional Advice to Control Early Psychiatric Symptoms
Reversal of Schizophrenia Memory Deficits
Switching Antipsychotic Medications in Schizophrenia: Why, When and How?
Can Substance Abuse Cause Psychosis?
The Epstein–Barr Virus and Schizophrenia
Antipsychotic polypharmacy and non-adherence
How to provide care for people with schizophrenia: challenges posed by the covid-19 pandemic
Biomarker Signature of Negative Symptoms
The hyperacute schizophrenic patient
News
COVID-19 and mental health
COVID-19 and the risk of developing mental health problems
COVID-19 and schizophrenia
COVID-19 and suicidality
Association between COVID-19 and psychiatric illnesses – a summary of different articles
Events
Log in required
Local regulations restrict this content to healthcare professionals
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/"target="_blank">Login</a>
Log in required
Local regulations restrict this content to healthcare professionals
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/" target="_blank">Login</a>
<a href="https://login.doccheck.com/code/com/2000000013340/l_red/" target="_blank">Login</a>
SCHIZOPHRENIA AWARENESS WEEK
Stay updated on current events
Recordati Webinar Program
ECNP Congress
2021
Evolving use of digital tools in schizophrenia assessment
Bridging adherence to long-term functioning in schizophrenia
Cognitive impairment in schizophrenia: the "big" unmet need
Living with schizophrenia after the covid-19 pandemic
2020
Symposium report: our product in schizophrenia
Can eating better improve people’s mental health?
Smartphone apps promise to support psychiatric practice
Exploring synaptic dysfunction in schizophrenia
Improving detection of young people at risk of psychoses
Exploring the druggable genome across psychiatric disorders
Managing psychosis in pregnancy still challenging
Early neurodevelopmental trauma induces adult psychosis
WFSBP 2021 Highlights
Towards digital-based care of schizophrenia: Where are we heading?
Cognitive impairment and negative symptoms in schizophrenia
Cariprazine as a broad-spectrum treatment
EPA Congress
2021
EPA SYMPOSIUM: Cariprazine throughout the stages of schizophrenia
Symposium: Polypharmacy in schizophrenia: A rational approach
LIVE-DEBATE: Should schizoaffective disorder be diagnosed cross-sectionally (ICD-11) instead of longitudinally (DSM-5)?
Cognitive Remediation in Schizophrenia
EPA SYMPOSIUM: Predicting outcomes in psychosis
LIVE ECP SYMPOSIUM: Personalised psychiatry in schizophrenia
LIVE: Personalising primary psychosis management
Early Intervention in Psychoses
Improving Real-life Functioning in People with Schizophrenia
Interventions, Neuroanatomy and Cognition in Psychoses
2020
Antipsychotic monotherapy or polypharmacy: what’s the evidence?
Best of 2019 article overview of research in schizophrenia
Integrated treatment for people with schizophrenia
Metacognition key to improving functioning in schizophrenia?
NEXT
How to provide care for people with schizophrenia: challenges posed by the COVID-19 pandemic
Beyond pharmacotherapy: Negative symptoms in the current literature
Cariprazine as a broad-spectrum treatment for patients with schizophrenia
Pharmacological treatment of negative symptoms in schizophrenia
Webinars
Psychiatry Update Webinars
Functioning and recovery in schizophrenia
Posetite ovaj odeljak
Schizophrenia
What is Schizophrenia?
Neurochemical basis of schizophrenia
Negative Symptoms
The Challenge of Negative Symptoms in Schizophrenia
Diagnosis
The Challenge of Diagnosing Negative Symptoms
Treatment
Burden
Treating Negative Symptoms of Schizophrenia
Lifestyle
How physical exercise helps individuals with schizophrenia
Our Product
Mode of Action
The Mechanism of Action of Our Product
Clinical Data
Efficacy
Our Product in patients with acute exacerbation of schizophrenia
Cariprazine in the Long-Term Treatment of Schizophrenia
Cariprazine Controls Negative Symptoms in Schizophrenia
Controlling Everyday Functioning with Cariprazine
Cariprazine's Effects on Primary and Secondary Negative Symptoms: The Pseudospecificity Problem
Safety
The Safety and Tolerability Profile of Our Product
The Management of Akathisia
Our product and Weight Gain
Prescribing Our Product
Initiating
Switching
Dosing
Drug-drug Interactions
Experience our product
Patients suitable for REAGILA
PATIENT SERIES: ACUTE PATIENTS
PATIENT SERIES: PATIENTS WITH NEGATIVE SYMPTOMS
PATIENT SERIES: THE SUBACUTE PATIENT
PATIENT SERIES: PATIENTS WITH THERAPEUTIC COMPROMISE – LACK OF EFFICACY
PATIENT SERIES: PATIENTS WITH THERAPEUTIC COMPROMISE – SAFETY ISSUES
Patient cases
A clinical case of patient with early psychosis treated with cariprazine
Our product add-on in inadequate clozapine response: a case study
Case Study of a Drug-Naïve Female Patient Treated With Cariprazine
Our product add-on in inadequate clozapine response: another case study
Early psychosis treated with cariprazine: a case study
Education & Resources
Diagnostic Tools
Diagnostic Tools
Interviews
Antagonist or partial agonist – which one is the best drug?
The role of partial agonists in schizophrenia treatment: managing the clinical aspects - ECNP 2020
Treatment with our product to address schizophrenia needs - ECNP 2020
Literature Review
Schizophrenia: negative symptoms
Cariprazine in the treatment of schizophrenia in clinical research and the real-world
The safety of recently developed antipsychotics
Dose-response in antipsychotics
Dosing antipsychotics in acute schizophrenia
Clinical guide for treating negative symptoms in schizophrenia
Understanding the pathophysiology of the negative symptom dimensions of schizophrenia
Validation of the PANSS in two-factor negative symptom distinction
Benefits of Antipsychotic Polypharmacy in Schizophrenia Maintenance Therapy
Schizophrenia: Is It All Down To Your Genes?
Causal Relationship Between Cognitive Deficit and Risk of Schizophrenia
Connection Between Inflammation and Schizophrenia?
Potential benefits of using eHealth in the management of schizophrenia
Markers of Inflammation and Infection in Schizophrenia
The Role of Cannabis in Treatment-Resistant Schizophrenia
Childhood Behaviour to Predict Psychosis-Spectrum Diagnoses in Adulthood
Suicide Prevention
Investigating the Stigma Around Mental Health and When People Seek Professional Advice to Control Early Psychiatric Symptoms
Reversal of Schizophrenia Memory Deficits
Switching Antipsychotic Medications in Schizophrenia: Why, When and How?
Can Substance Abuse Cause Psychosis?
The Epstein–Barr Virus and Schizophrenia
Antipsychotic polypharmacy and non-adherence
How to provide care for people with schizophrenia: challenges posed by the covid-19 pandemic
Biomarker Signature of Negative Symptoms
The hyperacute schizophrenic patient
News
COVID-19 and mental health
COVID-19 and the risk of developing mental health problems
COVID-19 and schizophrenia
COVID-19 and suicidality
Association between COVID-19 and psychiatric illnesses – a summary of different articles
Events
SCHIZOPHRENIA AWARENESS WEEK
Stay updated on current events
Recordati Webinar Program
ECNP Congress
2021
Evolving use of digital tools in schizophrenia assessment
Bridging adherence to long-term functioning in schizophrenia
Cognitive impairment in schizophrenia: the "big" unmet need
Living with schizophrenia after the covid-19 pandemic
2020
Symposium report: our product in schizophrenia
Can eating better improve people’s mental health?
Smartphone apps promise to support psychiatric practice
Exploring synaptic dysfunction in schizophrenia
Improving detection of young people at risk of psychoses
Exploring the druggable genome across psychiatric disorders
Managing psychosis in pregnancy still challenging
Early neurodevelopmental trauma induces adult psychosis
WFSBP 2021 Highlights
Towards digital-based care of schizophrenia: Where are we heading?
Cognitive impairment and negative symptoms in schizophrenia
Cariprazine as a broad-spectrum treatment
EPA Congress
2021
EPA SYMPOSIUM: Cariprazine throughout the stages of schizophrenia
Symposium: Polypharmacy in schizophrenia: A rational approach
LIVE-DEBATE: Should schizoaffective disorder be diagnosed cross-sectionally (ICD-11) instead of longitudinally (DSM-5)?
Cognitive Remediation in Schizophrenia
EPA SYMPOSIUM: Predicting outcomes in psychosis
LIVE ECP SYMPOSIUM: Personalised psychiatry in schizophrenia
LIVE: Personalising primary psychosis management
Early Intervention in Psychoses
Improving Real-life Functioning in People with Schizophrenia
Interventions, Neuroanatomy and Cognition in Psychoses
2020
Antipsychotic monotherapy or polypharmacy: what’s the evidence?
Best of 2019 article overview of research in schizophrenia
Integrated treatment for people with schizophrenia
Metacognition key to improving functioning in schizophrenia?
NEXT
How to provide care for people with schizophrenia: challenges posed by the COVID-19 pandemic
Beyond pharmacotherapy: Negative symptoms in the current literature
Cariprazine as a broad-spectrum treatment for patients with schizophrenia
Pharmacological treatment of negative symptoms in schizophrenia
Webinars
Psychiatry Update Webinars
Functioning and recovery in schizophrenia
Prijavite neželjenu reakciju
Serbia
Bulgaria
CZECH REPUBLIC
Denmark
Finland
International
Latvia
Netherlands
Norway
Poland
Romania
Russia
Slovakia
Slovenia
Spain
Sweden
Ukraine
Austria
Asean
sadržaj namenjen za opštu javnost
Log In | Register
Za zdravstvene radnike
Za opštu javnost
Literature Review
You are now leaving the site and will be re-directed to an external website.
Accept
Cancel
Showing
0
result(s).
Please log in to see
0
more result(s).
